MISSISSIPPI DIVISION OF MEDICAID
DRUG UTILIZATION REVIEW (DUR) BOARD
MINUTES OF THE MARCH 1, 2018 MEETING

ATTENDANCE SFY2018

DUR Board Members:	July 2017	Nov 2017	Mar 2018
Allison Bell, PharmD	✓	✓	NA
Rhonda Dunaway, RPh		✓	✓
Craig Escudé, MD (Chair)	✓		✓
Juanice Glaze, RPh		✓	✓
Alice Messer, DNP, FNP-BC	✓	✓	✓
Ray Montalvo, MD	NA	✓	✓
Holly Moore, PharmD	NA		✓
Janet Ricks, DO		✓	✓
Sue Simmons, MD		✓	
Dennis Smith, RPh	NA		✓
James Taylor, PharmD (Co-Chair)		✓	✓
Pearl Wales, PharmD	✓	✓	
TOTAL PRESENT	**4***	**9**	**9****

**Only 8 members were active due to new appointments to DUR Board not being approved by Governor prior to meeting.*
*** Only 11 members were active due to resignation resulting from move and replacement not yet approved by Governor.*

Also Present:

Division of Medicaid (DOM) Staff:
Terri Kirby, RPh, CPM, Pharmacy Director; Cindy Noble, PharmD, MPH, DUR Coordinator; Gail McCorkle, RPh, Clinical Pharmacist; Chris Yount, MA, PMP, Staff Officer – Pharmacy; Dorthy Young, PhD, Deputy Director of Health Services; Tami Brooks, MD, Medical Director; Mark Leiker, MA, Office Director of Mental Health; Brenda Allred, RN, Clinical Support Services; Shereen Wilson, RN, Clinical Support Services; Elizabeth Hargrove, University of Mississippi Pharmacy Intern

University of Mississippi School of Pharmacy - MS-DUR Staff:
Ben Banahan, PhD, MS-DUR Project Director; Eric Pittman, PharmD, MS-DUR Clinical Director; Manasi Suryavanshi, MS, MS-DUR Analyst

Conduent Staff:
Leslie Leon, PharmD, Clinical Pharmacist, Mississippi Medicaid Project

Change Healthcare Staff:
Shannon Hardwick, RPh, CPC Pharmacist; Cheryl Rogers, PharmD, Mississippi PA Pharmacist

Coordinated Care Organizations:
Heather Odem, PharmD, United Healthcare Community & State, Director of Pharmacy- Mississippi; Conor Smith, MS, RPh, Director of Pharmacy, Magnolia Health; Mike Todaro, PharmD, Vice President, Pharmacy Operations, Magnolia Health

Visitors:
Phil Hecht, Abbvie; Wendy Phillabaum, Supernus; Tim Hambacher, Otsuka; Jason Swartz, Otsuka; Gene Wingo, Biogen; Bob Firnberg, Gilead

Call to Order:
Dr. Escudé, Chair, called the meeting to order at 2:00pm. Dr. Escudé informed the board that this would be his last meeting to attend since he is moving out of the state. His effective resignation as a DUR Board member is April 30th, 2018. Dr. Noble and the DUR Board members thanked Dr. Escudé for his service and wished him well in the future.

Old Business:
Mr. Smith moved to approve the minutes from the November 2017 DUR Board Meeting, seconded by Ms. Glaze and unanimously approved by the DUR Board.

Resource Utilization Review:
Dr. Pittman informed the board that encounter data for Magnolia was incomplete for November when the report was run. This should not impact any of the resource utilization ranks, but does impact dollar amounts paid, number of claims, and number of beneficiaries for the month of November. No utilization shifts for this time of year were noted in terms of top categories by volume or dollars.

Pharmacy Program Update:
Ms. Kirby informed the Board members of recent provider notices regarding Magnolia and United Healthcare pharmacy reimbursement issues that occurred with some claims related to the new NADAC methodology.

The most recent PDL changes approved in February 13th Pharmacy and Therapeutics meeting will go into effect April 1, 2018.

N**EW BUSINESS**

Feedback and Discussion from the Board
Dr. Noble pointed out that the topic regarding proton pump inhibitor prescribing and utilization previously brought up by Dr. Taylor was being addressed in today's meeting. Dr. Escude' expressed thanks to the Board for recently addressing the use of antipsychotics in beneficiaries with intellectual and developmental disabilities (IDD).

Update on MS-DUR Educational Interventions
Dr. Pittman reviewed a new report included in the DUR packet regarding educational intervention mailings conducted during the prior quarter. He noted that these interventions are related to previous board recommendations.

Research Reports:

Review of Pharmacy Quality Alliance (PQA) Recommendations for Diabetes Medication Dosing and Utilization in Mississippi Medicaid

Dr. Banahan provided an overview of the included report. MS-DUR recommended no changes at this time.

Review of Stimulants and Related Agents in Mississippi Medicaid

Dr. Banahan provided an overview of the stimulant/non-stimulant analysis conducted by MS-DUR. After a thorough discussion, the following recommendations were made by the DUR Board:

1. DOM should check for ADD/ADHD or other compendia recognized conditions for children, adolescents, and adults who are prescribed stimulants to assure appropriate use and assure adequate monitoring of beneficiaries taking stimulants.
    a. The electronic PA process will allow the system to check for the ICD-10 diagnosis code and automatically adjudicate the stimulant prescription claim upon finding that diagnosis.
    b. The prescribing physician should be encouraged to write on the face of the prescription the appropriate diagnosis which the pharmacist can enter as part of claim for the prescription to be processed.
    c. If possible, a new start on stimulants for children should be allowed to go through on the first fill without a diagnosis with notification to provider that a diagnosis will be required for future fills.

Mr. Smith moved to approve recommendation number 1. The motion was seconded by Dr. Montalvo and approved unanimously.

2. MS-DUR should conduct an educational intervention about diagnoses requirements and encourage prescribers to write ICD-10 codes on prescriptions.

Mr. Smith moved to approve recommendation number 2, seconded by Dr. Moore and approved unanimously.

Proton Pump Inhibitor Use and Potential Deprescribing Opportunities in Mississippi Medicaid

Dr. Pittman provided an overview of the issue of potential overuse of proton pump inhibitors and the analyses conducted by MS-DUR. After a robust discussion, the following recommendations were proposed by the DUR Board:

1. DOM should set an electronic PA edit to limit the maximum days supply for PPI therapy to 90 days in a 12-month period before a PA is required.

Mr. Smith made a motion to accept recommendation number 1, seconded by Dr. Taylor and unanimously approved by the Board.

2. For therapy exceeding the 90 day limit, DOM should implement electronic or manual PA requirements for the maximum number of days supply based on diagnoses listed in Table 5 with addition of the condition of refractory GERD.

Ms. Dunaway made a motion to accept recommendation number 2, seconded by Dr. Montalvo and unanimously approved by the Board.

3. MS-DUR should implement an educational initiative notifying providers of the new PPI prescribing criteria and guidance on deprescribing. MS-DUR should consider educational mailings to beneficiaries, if feasible.

Dr. Messer made a motion to accept recommendation number 3, seconded by Mr. Smith and unanimously approved by the Board. Dr. Montalvo volunteered to help compile a list of alternative treatments and behavioral modifications.

FDA Drug Safety Updates
MS-DUR reviewed recent FDA drug safety communications with the Board.

Next Meeting Information:
Dr. Escudé announced that the next meeting of the DUR Board will take place on May 31, 2018 at 2:00 p.m. He thanked everyone for their attendance and participation at the March 1, 2018 DUR Board meeting.

The meeting adjourned at 3:43 pm.

Submitted,
Eric Pittman, PharmD, Evidence-Based DUR Initiative, MS-DUR
PUBLIC MEETING NOTICES



Meeting Location: Woolfolk Building, 501 North West Street, Conference Room 117 Jackson, MS 39201

Contact Information: Pharmacy Bureau:
Chris Yount, 601-359-5253: Christopher.yount@medicaid.ms.gov, or
Jessica Tyson, 601-359-5253; Jessica.Tyson@medicaid.ms.gov

Notice details:

State Agency: MS Division of Medicaid

Public Body: Drug Utilization Board (DUR) Meeting

Subject: Quarterly Meeting

Date and Time: March 1, 2018 at 2 PM

Description: The Mississippi Division of Medicaid's Drug Utilization Review (DUR) Board is a quality assurance body which seeks to assure appropriate drug therapy to include optimal beneficiary outcomes and appropriate education for physicians, pharmacists, and the beneficiary. The Drug Utilization Review (DUR) Board is composed of twelve participating physicians and pharmacists who are active MS Medicaid providers and in good standing with their representative organizations.

The Board reviews utilization of drug therapy and evaluates the long-term success of the treatments.

The Drug Utilization Review (DUR) Board meets quarterly.